[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![BioCentury Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::227778014.png) BioCentury [@BioCentury](/creator/twitter/BioCentury) on x 16.3K followers
Created: 2025-07-15 22:30:12 UTC

Rare disease setbacks for Ultragenyx, mid-stage win for Rhythm. Plus: Astrazeneca and Takeda preparing submissions after Phase III readouts, in this week’s Clinical Report

![](https://pbs.twimg.com/card_img/1945249615625756672/rT0E4A55?format=jpg&name=800x419)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945249566049095747/c:line.svg)

**Related Topics**
[$azn](/topic/$azn)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/BioCentury/status/1945249566049095747)